Drug Profile


Alternative Names: CP 1552S

Latest Information Update: 05 Oct 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Continental Pharma
  • Class Antidepressants; Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action Glycine agonists; Glycine NMDA-associated agonists; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alzheimer's disease; Psychotic disorders
  • Discontinued Epilepsy

Most Recent Events

  • 05 Oct 2001 Discontinued-III for Epilepsy in United Kingdom (Unknown route)
  • 05 Oct 2001 Discontinued-III for Epilepsy in USA (Unknown route)
  • 04 Oct 2001 No-Development-Reported for Alzheimer's disease in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top